A comparative sNPWT study of 10,000+ C-sections shows PICO™ sNPWT reduces complications and cuts healthcare costs by $728,000 per 1,000 patients
Article content
Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces findings from a newly published comparative study of single-use Negative Pressure Wound Therapy (sNPWT) devices in Caesarean section (C-section) recovery has identified significant benefits for postpartum use of Smith+Nephew's leading PICO sNPWT technology. Analyzing real-world data from over 10,000 C-section patients treated at different pressure levels, the study published in WOUNDS (April 2025) reveals that PICO sNPWT contributes to a significant reduction in surgical site complications (SSCs), including a reduction in the incidence of surgical site infections (SSIs), wound dehiscence and seroma, and overall costs, compared to another sNPWT device (P≤0.05). 1
Article content
Article content
Article content
New survey: The real-life burden of C-section complications
A complementary survey of new mothers who have undergone C-sections highlighted the impact of SSCs on both mother and baby: 2
Article content
Dr. Tia Welsh, M.D. Chair of Obstetrics and Gynecology at Valley Medical Group and co-author of the study added, ' Postpartum is already a very vulnerable period for mothers, even without complications. SSCs add physical pain, prolonged recoveries, emotional distress, and disrupt critical early bonding with newborns. These interruptions carry emotional and practical burdens, increasing the risks of postpartum depression, anxiety, and trauma – costs that can't be captured in dollars alone.'
Article content
Article content
Real-world data shows the clinical and economic benefits of using PICO sNPWT in patients undergoing C-section procedures
The study used real-world evidence from the Premier PINC AI™ Healthcare Database to analyze outcomes from a geographically diverse mix of community hospitals, teaching hospitals and healthcare systems across the US.
Notable findings include significant reductions with PICO sNPWT, compared to other sNPWT devices in the incidence of*:
Article content
Overall SSIs (p=0.018)
Superficial SSIs (p=0.017)
Wound dehiscence (p=0.005)
Seroma formation(p=0.050)
Article content
'We've long understood the benefits of NPWT in surgical recovery, but this is the first large-scale study to directly compare different pressure levels in a real-world setting,'
said Dr. Annmarie Vilkins, DO. Director of Obstetrics and Gynaecology at Henry Ford Health, and the study's lead author. 'We found that PICO sNPWT showed significantly improved outcomes through optimizing pressure, fluid management, and skin adhesion. Its unique design helped maintain a high moisture vapor transmission rate supporting an ideal healing environment for recovery, particularly critical for high-risk incisions like C-sections under skin folds, where moisture buildup can lead to infection.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Cision Canada
14 hours ago
- Cision Canada
Ambassadors Accelerate CarePatrol's AlignedCare™ Program
Beta testing begins for proprietary value-based care model driven by advisor insights OTTAWA, Ontario, June 9, 2025 /CNW/ -- CarePatrol, a leading senior care solutions franchise with more than 200 locations open across 40 states and Canada, is advancing its proprietary AlignedCare™ Value-Based Care (VBC) Certification Program with the selection of its first Ambassador team. The select group of experienced advisors will act as early adopters, leading beta testing and shaping the future for value-based care integration within senior care advisory services. The AlignedCare Program represents a transformative step in how care solutions are guided and recommended. Advisors who complete the certification will be qualified to support families using an evidence-informed model based on outcomes, social determinants of health, and care collaboration. Built on value-based care principles informed by the 8 Dimensions of Wellness, the program enables higher levels of client precision and personalization, while also expanding value-based care partnership networks. Throughout the beta phase, AlignedCare Ambassadors will be applying the model within their current practices and providing critical feedback on assessment tools, strategic workflows, and outcomes tracking. Insights provided and gained during this phase will assist in system-wide implementation. "We're thrilled with the early momentum of the AlignedCare Program and the enthusiasm from our Ambassador team," said Becky Bongiovanni, co-founder and brand president of CarePatrol. "Our advisors are stepping into a leadership role that goes far beyond traditional care advisory. By aligning every recommendation with value-based care principles, we are building a more complete, measurable, and compassionate model for senior care." Each AlignedCare Ambassador plays a vital role in strengthening CarePatrol's mission to strengthen senior care advisory services through professional development, collaboration, and meaningful community impact. This next phase of the initiative builds on CarePatrol's legacy of innovation, using evidence-informed practices to deliver personalized, outcome-focused advisory solutions. A full system-wide rollout of the AlignedCare™ Certification Program is anticipated later this year. About CarePatrol CarePatrol is the nation's largest senior care solutions franchise in the United States. With more than 225 locations sold across 40 states and Canada, local senior advisors provide a no-cost service in helping families find quality, top-rated independent living, assisted living, memory care, long-term care, and home care. Founded in 1993, CarePatrol began franchising in 2009 and is now part of the Best Life Brands family, with private equity backing by The Riverside Company. CarePatrol is proud to have earned the Franchisee Satisfaction Award from Franchise Business Review for 14 years in a row, including its induction into the Hall of Fame in 2024, and has earned placement on the Entrepreneur Franchise 500 list. For more information, visit
Cision Canada
17 hours ago
- Cision Canada
DRI Healthcare Trust Announces Appointment of Annalisa King to Board of Trustees and as Chair of the Audit Committee
– Adds extensive expertise in audit, risk and financial strategy – TORONTO, June 9, 2025 /CNW/ - DRI Healthcare Trust (TSX: (TSX: DHT.U) ("DRI" or "the Trust") today announced Annalisa King has been appointed as an independent member and chair of the audit committee of the Trust's board of trustees effective immediately. Ms. King is the chair of the board for Vancouver Airport Authority and an experienced corporate director serving on three TSX public company boards. She is the chair of the audit committee at both Saputo Inc. and The North West Company Inc. and is the chair of the compensation committee at First Capital Real Estate Investment Trust. In addition to her board work, Ms. King is the National Academic Director of the Board Oversight of Strategy course at the Institute of Corporate Directors. Ms. King was the Senior Vice President and Chief Financial Officer of Best Buy Canada Ltd. from 2008 to 2016, where, in addition to her finance responsibilities, she also led the information technology, ecommerce technology, cyber security, legal and real estate functions. Recognized in 2012 as the British Columbia CFO of the Year by Business in Vancouver, Ms. King is one of Canada's most respected senior business executives. She received the award for Significant Board Contribution by the Association of Women in Finance in 2019 and was inducted into the Canada's Most Powerful Women: Top 100 Hall of Fame™ in 2010. Her dedication to leadership has earned her a reputation as a dynamic business thought-leader in the areas of corporate finance and business transformation. "On behalf of the Trust and my fellow trustees, I am very pleased to welcome Annalisa King to the board," said Gary Collins, the Trust's Chief Executive Officer and Chairman. "Annalisa's extensive audit, risk and financial experience provides a strong addition to the board. I look forward to working with her on behalf of our unitholders." With the addition of Ms. King, the Trust's board is now made up of eight members with backgrounds in the areas of pharmaceuticals, government, business, finance, law, cybersecurity and governance, all critical to the continued growth and prosperity of the Trust. The Trust is managed by DRI Capital Inc., a pioneer in global pharmaceutical royalty monetization. Since its initial public offering in 2021, the Trust has deployed more than $1.0 billion, acquiring more than 25 royalties on 20-plus drugs, including Eylea, Orserdu, Omidria, Spinraza, Stelara, Vonjo, Zejula and Zytiga. The Trust's units are listed and trade on the Toronto Stock Exchange in Canadian dollars under the symbol " and in U.S. dollars under the symbol "DHT.U". To learn more, visit or follow us on LinkedIn.
Globe and Mail
a day ago
- Globe and Mail
Hims & Hers Stock Is Soaring Again. But Should You Buy the Stock?
Many companies have failed to disrupt the complicated U.S. healthcare market. Hims & Hers (NYSE: HIMS) may finally be succeeding in cracking the code. The online telehealth platform focuses on circumventing the insurance market; its business of selling affordable medications directly to individuals is growing like a weed, and expects to generate $6.5 billion in revenue by 2030. It has had a tumultuous start to 2025, as Hims & Hers waged a battle to sell new weight loss medications on its online marketplace. Now, with momentum back on its side, the stock is up 118% year to date and 446% in the last five years. Let's take a deeper look at this company, and see whether you might want to buy Hims & Hers stock for your portfolio now. Disrupting the healthcare market Hims & Hers' model is simple. It has two separate web platforms -- Hims for men and Hers for women -- that sell medications and deliver to customers' front doors. It began with sexual health, but has moved into dermatology, hair loss, mental health, and now weight loss medications. A key to its success has been avoiding the insurance market with products that don't break the bank. Customers loathe dealing with health insurers in the United States, and sometimes would rather not use insurance at all. Plus, some of these products aren't covered by insurance. This strategy has helped the company close in on over $2 billion in projected revenue in 2025. To keep up this impressive growth, Hims & Hers wants to offer weight loss medications, which have been a blockbuster set of drugs for the pharmaceutical market. For a while the popularity of these drugs, such as Novo Nordisk 's Wegovy, left them in short supply; that allowed third parties such as Hims & Hers to produce them as a compounding pharmacy and sell them at much cheaper prices. This ended up generating $200 million of Hims & Hers' $1.4 billion in 2024 revenue. But with the shortage of Wegovy over and the compounding pharmacy exception ended, the company's weight-loss business was at a major turning point. Luckily, at the end of April Hims & Hers announced a partnership with Novo Nordisk that seems to resolve this issue: It gives Hims & Hers the ability to sell Wegovy directly on its platform. Hims & Hers is not an exclusive supplier of the drug -- or any drugs on its marketplaces, to be fair -- but it hopes to use its subscription business model, marketing expertise, and simplified user proposition to drive sales for Novo Nordisk in the huge obesity-care market. Going abroad and personalization Besides weight loss drugs, Hims & Hers has more ambitions to reach its goal of $6.5 billion in revenue by 2030. Just recently, the company announced its intent to acquire European competitor Zava so it could expand its telehealth service to Europe. The acquisition will add a platform with 1.3 million active customers in the U.K., Germany, France, and Ireland. It makes sense that Hims & Hers can supercharge growth for the platform with its plethora of medications offered to customers, keen marketing skills, and subscription-based selling model. Over the long run, Hims & Hers aims to make healthcare for its customers more personalized. This includes unique drug combinations, its own outsourcing facility, and at-home testing capabilities. Details remain sparse, but the vision is clear: disrupting more and more of the trillions of dollars spent on healthcare by building a business that people actually enjoy interacting with. This is why 2.4 million active customers use Hims & Hers today. HIMS Gross Profit Margin data by YCharts. Should you buy Hims & Hers stock? A revenue goal of $6.5 billion seems well within reach by 2030. Hims & Hers is only at 2.4 million active customers, and there are tens of millions of people in the United States alone who could start using or switch to one of its telehealth platforms. Add on the Zava acquisition in Europe, and the runway for growth gets even larger. The company has an impressive gross profit margin of 77%, which should lead to high levels of profitability at scale. On $6.5 billion in future revenue, it could very well post a net profit margin of over 20%, and achieve $1.5 billion in bottom-line profits and free cash flow. A 20% profit margin is easily achievable because of its high gross margins and the fact it currently spends 40% of revenue on marketing today, a figure that has come down over time and should come down even more as Hims & Hers keeps scaling. However, Hims & Hers has played fast and loose with laws and regulations in the past. It sold weight loss drugs when the legality of doing so was unclear, and although that dispute seems to have been resolved, management could easily start playing with fire again and burn its reputation as a trusted provider of medications. Otherwise, this looks like a fantastic growth stock that just doubled its addressable market with the Zava acquisition. Today, Hims & Hers has a market cap of $12.3 billion. You might think it's overvalued because of the stock's recent run-up in price, but the numbers show that patient investors could be rewarded by holding for the long term. A $12.3 billion market cap is only around 8 times my 2030 earnings estimate of $1.5 billion, which would be a dirt cheap price-to-earnings (P/E) ratio for a fast-growing company compared to the current market cap. Most likely, the stock will be valued at a higher multiple than 8, meaning that the stock will be higher in five years. It doesn't come without risks, but if you're a growth investor, you might love Hims & Hers stock for its long-term potential. Should you invest $1,000 in Hims & Hers Health right now? Before you buy stock in Hims & Hers Health, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Hims & Hers Health wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $669,517!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $868,615!* Now, it's worth noting Stock Advisor 's total average return is792% — a market-crushing outperformance compared to173%for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of June 2, 2025
